Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Beta-amyloid (Abeta) oligomers are increasingly recognized as the primary toxic species in Alzheimer's disease (AD), impairing synaptic plasticity and long-term potentiation (LTP).
• Neutralizing the toxicity of Abeta oligomers has shown promise in reversing memory deficits associated with AD.

Purpose of the Study:

• To isolate and characterize novel antibodies that specifically target toxic Abeta oligomers.
• To evaluate the potential therapeutic and diagnostic applications of these conformation-dependent antibodies in AD.

Main Methods:

• Phage display technology was employed to screen a naive human scFv library.
• Four single-chain variable fragment (scFv) antibodies were isolated based on their specific recognition of Abeta oligomers.

Main Results:

• The isolated scFv antibodies demonstrated specificity for Abeta oligomers, distinguishing them from monomers and fibrils.
• These antibodies were found to inhibit both Abeta fibrillation and cytotoxicity.
• The scFv antibodies bind to a common epitope displayed on toxic Abeta oligomers.

Conclusions:

• Conformation-dependent scFv antibodies targeting toxic Abeta oligomers represent a promising strategy for AD intervention.
• These antibodies hold potential for both therapeutic development and diagnostic tools in Alzheimer's disease research and clinical practice.